Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | MAT2A | P31153 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10335042 | 0.87 | MEN1 (0.48) | L3MBTL1MEN1LMNAKMT2ADRD2 | |
| SCHEMBL2718551 | 0.78 | LMNA (0.51) | MEN1LMNAKMT2ADAOHPGD | |
| SCHEMBL3066593 | 0.70 | LMNA (0.57) | L3MBTL1MEN1LMNAKMT2ADRD2 | |
| SCHEMBL5657109 | 0.70 | OPRM1 (0.43) | L3MBTL1MEN1KMT2ADAOTSHR | |
| SCHEMBL8139346 | 0.70 | KDM4E (0.44) | L3MBTL1MEN1LMNAKMT2AHTR2A | |
| SCHEMBL26666399 | 0.69 | DRD2 (0.70) | MEN1LMNAKMT2ADRD2HTR1A | |
| SCHEMBL16997517 | 0.68 | MEN1 (0.54) | L3MBTL1MEN1LMNAKMT2ADRD2 | |
| SCHEMBL4444487 | 0.67 | CHRM1 (0.72) | MEN1LMNAKMT2ADRD2HTR1A | |
| SCHEMBL7371675 | 0.67 | MAPT (0.67) | L3MBTL1MEN1LMNAKMT2ADAO | |
| SCHEMBL640787 | 0.67 | MEN1 (0.56) | L3MBTL1MEN1LMNAKMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | claimed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| EP-2447266-B1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LTD (GB) | 2013-06-12 | — | — | EP | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| EP-1868611-B1 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES | GLAXO GROUP LTD (GB) | 2012-11-14 | — | — | EP | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| US-20040116435-A1 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | L3MBTL1 3390/4885MEN1 3164/4885LMNA 4544/4885 |
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | L3MBTL1 1988/4885MEN1 4590/4885LMNA 4002/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | L3MBTL1 1552/4885MEN1 4506/4885LMNA 4027/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | L3MBTL1 1552/4885MEN1 4506/4885LMNA 4027/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | L3MBTL1 1988/4885MEN1 4590/4885LMNA 4002/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | L3MBTL1 1552/4885MEN1 4506/4885LMNA 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.